Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy. [electronic resource]
Producer: 20190502Description: 363-374 p. digitalISSN:- 1744-8379
- Antiviral Agents -- administration & dosage
- Benzimidazoles -- administration & dosage
- Carbamates
- Cohort Studies
- Cost-Benefit Analysis
- Drug Therapy, Combination
- Fluorenes -- administration & dosage
- Genotype
- Hepatitis C, Chronic -- drug therapy
- Humans
- Imidazoles -- administration & dosage
- Italy
- Markov Chains
- Pyrrolidines
- Quality-Adjusted Life Years
- Ribavirin -- administration & dosage
- Simeprevir -- administration & dosage
- Sofosbuvir -- administration & dosage
- Uridine Monophosphate -- administration & dosage
- Valine -- analogs & derivatives
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.